Triastek, an Early Yunqi Capital Portfolio Company, Closes New Strategic Funding Round, Launching New Oral Peptide Strategy | Yunqi Capital

Yunqi Capital portfolio company Triastek has announced a new strategic funding round, with investors including Minjin Investment, Lingang Digital Technology, and Hangzhou Industrial Investment Group.

The proceeds will primarily fund the construction of Triastek's Shanghai International R&D and Production Center, clinical advancement of its oral peptide pipeline, and expansion of international partnerships. Leveraging its self-developed 3D microstructure oral macromolecule delivery platform, Triastek is establishing oral peptides as a new strategic priority, aiming to solve the long-standing delivery challenge that has kept biologic drugs dependent on injection. Learn more in this edition of "Yunqi Partners."

The following is adapted from VBData (动脉网)

01 Triastek's New Strategy: Focus on Oral Peptides

Oral peptides have long faced delivery challenges including gastrointestinal degradation and low mucosal permeability, leaving most dependent on injectable administration with limited patient compliance. As the population of chronic disease patients continues to grow, clinical demand for safe and effective oral peptide drugs has become increasingly urgent. Addressing this core pain point, Triastek has established oral peptides as a new strategic priority, committed to breaking through delivery barriers with novel technology and expanding its platform's broad application in oral biologic drugs.

Triastek's self-developed 3D microstructure oral macromolecule (3DμS-OM) delivery platform employs MED&SSE (melt extrusion deposition combined with semi-solid extrusion) 3D printing technology, which effectively maintains the stability of peptide and macromolecule raw materials during production. Through strategic design of formulation structure and shell materials, the platform precisely delivers drugs to the optimal absorption window in the gastrointestinal tract, thereby improving bioavailability of oral peptide formulations and reducing food effects.

Based on this platform, Triastek's key product T25 (octreotide acetate tablets) has received clinical trial approval for new drugs in both China and the US for the treatment of acromegaly. The pipeline progress of T25 has preliminarily validated the translational potential of the 3DμS-OM platform in oral peptides, achieving a critical leap from technology validation to product development and laying a solid foundation for the company's continued expansion in oral peptides.

02 Building a New Pattern for Oral Peptide Drug Development and International Cooperation

As the only company in China holding a 3D-printed drug production license, Triastek has built a full-chain technology platform covering drug dosage form design, digital development, and continuous manufacturing. The differentiated technical advantages of the 3DμS-OM platform in oral macromolecule delivery provide core competitiveness for the company's industrial transformation and international cooperation in this new phase.

The establishment of the Shanghai International R&D and Production Center marks Triastek's transition from technology platform construction to industrial capability building in its oral peptide strategy. The center will leverage Shanghai's biopharmaceutical industry ecosystem to systematically build an integrated platform combining clinical research, industrial development, and international cooperation, forming a complete closed-loop capability from product development to global commercialization. This layout will significantly expand the company's strategic depth in oral biologics.

Senping Cheng, Founder and CEO of Triastek, said: "We are especially grateful for the trust and support from shareholders including Minjin Investment, Lingang Digital Technology, and Hangzhou Industrial Investment Group, and sincerely thank our existing shareholders for their steadfast companionship. This funding will strongly support the development of our oral peptide strategy. We look forward to the Shanghai International R&D and Production Center accelerating the clinical and industrial progress of our oral peptide pipeline, and serving as a bridge to explore more possibilities of 3D printing pharmaceutical technology in oral biologics together with global partners, so that innovative outcomes can benefit patients sooner."